
    
      PERFORMANCE AND SAFETY VARIABLES:

      The primary efficacy endpoint for this study is the total Chronic obstructive pulmonary
      disease (COPD) Assessment Test (CAT) score change from baseline to the 8 week follow-up
      period comparing the two device groups.

      Secondary efficacy endpoints will be the mean difference from baseline to the 8 week
      follow-up for the following assessments: Medical Research Council (MRC) dyspnoea scale, 6
      minutes walking test and Forced Expiratory Volume in one second (FEV1)

      Safety Variables:

      Each subject will be assessed throughout the study for Adverse Events and at the last visit
      (4 months) subjects will undergo another physical examination including vital signs and blood
      pressure.
    
  